GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Cyclically Adjusted Book per Share

TG Therapeutics (STU:NKB2) Cyclically Adjusted Book per Share : €1.44 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

TG Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was €0.953. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.44 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of TG Therapeutics was 74.20% per year. The lowest was -63.80% per year. And the median was -39.20% per year.

As of today (2024-05-23), TG Therapeutics's current stock price is €15.108. TG Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €1.44. TG Therapeutics's Cyclically Adjusted PB Ratio of today is 10.49.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 30.56. The lowest was 0.03. And the median was 3.93.


TG Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for TG Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Cyclically Adjusted Book per Share Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.71 -0.83 1.29 1.30 1.39

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.36 1.46 1.39 1.44

Competitive Comparison of TG Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, TG Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Cyclically Adjusted PB Ratio falls into.



TG Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.953/131.7762*131.7762
=0.953

Current CPI (Mar. 2024) = 131.7762.

TG Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.006 100.560 1.318
201409 1.256 100.428 1.648
201412 1.446 99.070 1.923
201503 2.069 99.621 2.737
201506 1.948 100.684 2.550
201509 1.973 100.392 2.590
201512 1.725 99.792 2.278
201603 1.485 100.470 1.948
201606 1.286 101.688 1.667
201609 0.924 101.861 1.195
201612 0.599 101.863 0.775
201703 1.415 102.862 1.813
201706 1.019 103.349 1.299
201709 0.945 104.136 1.196
201712 0.774 104.011 0.981
201803 0.897 105.290 1.123
201806 1.052 106.317 1.304
201809 0.741 106.507 0.917
201812 0.252 105.998 0.313
201903 0.192 107.251 0.236
201906 0.125 108.070 0.152
201909 -0.242 108.329 -0.294
201912 0.318 108.420 0.387
202003 -0.011 108.902 -0.013
202006 1.362 108.767 1.650
202009 1.124 109.815 1.349
202012 3.037 109.897 3.642
202103 2.644 111.754 3.118
202106 2.226 114.631 2.559
202109 1.852 115.734 2.109
202112 1.465 117.630 1.641
202203 1.070 121.301 1.162
202206 0.841 125.017 0.886
202209 0.698 125.227 0.735
202212 0.378 125.222 0.398
202303 0.172 127.348 0.178
202306 0.247 128.729 0.253
202309 1.019 129.860 1.034
202312 0.972 129.419 0.990
202403 0.953 131.776 0.953

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


TG Therapeutics  (STU:NKB2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

TG Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=15.108/1.44
=10.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 30.56. The lowest was 0.03. And the median was 3.93.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


TG Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (STU:NKB2) Business Description

Industry
Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines